It has been found that antimuscarinic drugs, viewed as the "gold standard" in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5603/GP.a2017.0092 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!